Aptose Biosciences Files 8-K
Ticker: APTOF · Form: 8-K · Filed: May 6, 2024 · CIK: 882361
Sentiment: neutral
Topics: disclosure, financials, regulation-fd
Related Tickers: APTO
TL;DR
APTO filed an 8-K on May 6th covering Reg FD and financials.
AI Summary
Aptose Biosciences Inc. filed an 8-K on May 6, 2024, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Lorus Therapeutics Inc. and Imutec Pharma Inc., is incorporated in Canada and operates in the biological products sector.
Why It Matters
This filing provides updates on Aptose Biosciences' regulatory and financial disclosures, which are important for investors to understand the company's current status and compliance.
Risk Assessment
Risk Level: low — This filing is a routine disclosure and does not contain significant new information that would inherently increase risk.
Key Players & Entities
- Aptose Biosciences Inc. (company) — Registrant
- Lorus Therapeutics Inc. (company) — Former Company Name
- Imutec Pharma Inc (company) — Former Company Name
- May 6, 2024 (date) — Date of Report
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing serves as a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, covering Regulation FD Disclosure and Financial Statements and Exhibits.
When was this 8-K filed?
The 8-K was filed on May 6, 2024.
What are the former names of Aptose Biosciences Inc.?
Aptose Biosciences Inc. was formerly known as Lorus Therapeutics Inc. and Imutec Pharma Inc.
In which jurisdiction is Aptose Biosciences Inc. incorporated?
Aptose Biosciences Inc. is incorporated in Canada.
What is the Standard Industrial Classification code for Aptose Biosciences Inc.?
The Standard Industrial Classification code for Aptose Biosciences Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 495 words · 2 min read · ~2 pages · Grade level 9.6 · Accepted 2024-05-06 16:45:13
Filing Documents
- f8k_050624.htm (8-K) — 14KB
- exh_991.htm (EX-99.1) — 5KB
- 0001171843-24-002578.txt ( ) — 216KB
- gnw-20190101.xsd (EX-101.SCH) — 3KB
- gnw-20190101_def.xml (EX-101.DEF) — 25KB
- gnw-20190101_lab.xml (EX-101.LAB) — 33KB
- gnw-20190101_pre.xml (EX-101.PRE) — 22KB
- f8k_050624_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On May 6, 2024, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. 99.1 Press Release dated May 6, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aptose Biosciences Inc. Date: May 6, 2024 By: /s/ William G. Rice, Ph.D. William G. Rice, Ph.D. Chairman, President, and Chief Executive Officer